Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing
Mandate

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

August 28, 2025 Capital Markets and Public M&A Banking and Finance

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.

Xspray is a pharmaceutical company that specializes in using its patented HyNap-technology to develop improved versions of existing protein kinase inhibitors (PKIs) for cancer treatment.

Vinge’s team consisted of Dain Hård Nevonen, Joel Magnusson, Louise Nässén and Amanda Sandström (Capital Markets and Public M&A) as well as Arvid Weimers (Banking and Finance).

Related

Vinge advises Borgo in connection with its inaugural issuance of primary capital instruments (AT1)

 Vinge has advised Borgo AB (publ) in connection with its successful issuance of primary capital instruments (so called “AT1 bonds”) in the amount of SEK 350 million with a floating rate coupon of 3-month STIBOR + 390 basis points.
January 29, 2026

Vinge advises J Bil in conjunction with the acquisition of Appelskog Bil AB

 Vinge has advised the buyer J Bil AB in conjunction with the acquisition of all shares in Appelskog Bil AB.
January 29, 2026

Vinge has advised United Lithium Corp. in connection with the acquisition of Swedish Minerals AB

 United Lithium is an exploration & development company focused on the global demand for lithium, uranium and rare earth elements.
January 29, 2026